According to relevant reports, a bispecific split CAR (BissCAR) T cell targeting CD13 and TIM-3 has a significant effect in clearing patient-derived acute myeloid leukemia (AML). The gene discussed is HAVCR2; the disease is acute myeloid leukemia.